Blog
Analysis and insights on organ-on-chip technology, regulatory developments, digital twins, and the companies driving the shift to human-relevant drug testing.
FDA Modernization Act 3.0: What It Means for Drug Testing in 2025
The FDA Modernization Act 3.0 eliminates the federal mandate requiring animal testing before human clinical trials. This analysis covers the full regulatory impact, what changed from the original 1938 law, and how pharma companies are adapting their preclinical pipelines.
Organ-on-Chip Technology Explained: How Microfluidic Devices Replace Animal Testing
A deep dive into how microfluidic chips lined with living human cells simulate organ physiology, from lung-on-chip to multi-organ systems. Includes current FDA-qualified platforms and clinical validation data.
IndustryTop 15 Biotech Companies Leading the NAMs Revolution
Profiles of the companies building organ-on-chip platforms, organoid systems, and computational models that are replacing animal testing in pharmaceutical R&D. Market data, funding rounds, and technology comparisons.
ScienceNew Approach Methodologies (NAMs): A Complete Guide for Researchers
What are NAMs, how do they work, and why are regulatory agencies adopting them? This guide covers organoids, organ-on-chip, in silico models, and the validation pathways making them viable replacements for animal studies.
ResearchDigital Twins in Drug Discovery: From Patient Data to Virtual Clinical Trials
How computational models of individual patients are transforming drug development. Covers multi-omic integration, virtual population modeling, and real-world case studies from Roche, Novartis, and Unilever.